Keros Therapeutics, Inc. KROS
11.62
0.07
0.61%
as of 25 Sep
- Market cap
- $229.0M
- P/E
- 0.0×
Follow KROS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
10.01 | 10.95 | 0.00 | — |
P/S ratio |
2.60 | 3.11 | 6.53 | — | |
P/FCF ratio |
7.38 | 7.15 | 0.00 | — | |
P/Operating CF |
197.80 | (27.77) | (61.41) | — | |
P/B ratio |
0.91 | 2.50 | 0.76 | — | |
Price to Tangible BV |
0.91 | 2.50 | 0.76 | — | |
EV/Sales |
(0.21) | 1.93 | (1.95) | — | |
EV/EBITDA |
0.00 | 6.81 | 0.60 | — | |
EV/Operating CF |
(0.57) | 4.38 | 1.13 | — | |
EV/FCF |
(0.58) | 4.44 | 1.11 | — | |
Quick Ratio |
28.93 | 14.36 | 22.11 | 21.38 | |
Current Ratio |
29.86 | 15.45 | 22.62 | 21.96 | |
Net Debt/EBITDA |
46.27 | 9.96 | 11.05 | 8.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.37 | 0.51 | 0.06 | 0.00 | |
Operating CF/Net income |
(0.45) | 1.16 | 0.15 | 0.71 | |
Capex/Depreciation |
(0.33) | (0.33) | (0.18) | (0.39) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
136.86% | 4,652.47% | 4,386.10% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
71.01% | 3,050.13% | 2,764.85% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
27.95% | 1,897.40% | 1,689.10% | 0.00% | |
Graham Net Nets |
1.06 | 0.37 | 1.22 | — | |
Graham Number |
24.81 | 18.46 | 0.00 | — | |
Earnings Yield |
9.99% | 9.14% | (27.26%) | — | |
Free Cash Flow Yield |
13.55% | 13.98% | (26.88%) | — | |
Revenue per Share |
0.35 | 0.01 | 0.02 | 0.00 | |
Operating CF per Share |
0.08 | (0.73) | (0.18) | (1.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.08 | (0.74) | (0.18) | (1.04) | |
Cash per Share |
17.07 | 7.72 | 14.34 | 13.01 | |
Shareholders Equity per Share |
17.32 | 8.14 | 14.55 | 13.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.32 | 8.14 | 14.55 | 13.25 | |
Free Cash Flow |
3.12 | (27.43) | (3.60) | (20.58) | |
Working Capital |
695.22 | 295.02 | 277.82 | 254.73 | |
Capital Expenditures |
(0.13) | (0.13) | (0.07) | (0.15) | |
Net Current Asset Value |
680.10 | 280.55 | 264.01 | 241.60 | |
EV/EBIT |
0.00 | 6.96 | 0.59 | — | |
Capex to Sales |
0.01 | 0.35 | 0.20 | 0.00 | |
Net Profit Margin |
(51.04%) | (6,093.77%) | (6,459.95%) | 0.00% | |
Price to Operating Income |
14.74 | 11.22 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
1.94 | 4.28 | 9.97 | 9.03 | |
Average Payables |
3.64 | 3.28 | 4.06 | 3.54 | |
Average Assets |
661.03 | 476.95 | 548.43 | 522.38 | |
Average Common Equity |
618.21 | 437.34 | 507.25 | 484.53 |
Columns are period end dates